Subarachnoid Hemorrhage, AneurysmalDelayed Cerebral IschemiaCerebral Vasospasm After Subarachnoid HemorrhageIntracranial Aneurysm
Study summary
The goal of this observational study is to investigate DNA methylation changes in adults with bleeding from brain aneurysm, which is called aneurysmal subarachnoid hemorrhage (aSAH), and their association with delayed ischemic neurologic deficit (DIND). The main questions it aims to answer are:
Are there specific DNA methylation changes in peripheral blood that differentiate patients with aSAH from healthy individuals? Can DNA methylation changes in peripheral blood predict the development of DIND following aSAH? Researchers will compare blood DNA methylation profiles of aSAH patients to healthy controls and also do subgroup analysis of patients with DIND versus those without DIND to see if there are distinct methylation patterns associated with aSAH and DIND.
Participants with aSAH will:
* Have a blood sample collected shortly after admission to hospital.
* Undergo epigenome-wide DNA methylation profiling using the Infinium MethylationEPIC v2.0 BeadChip microarray.
* Be monitored for the development of DIND, defined by clinical symptoms and radiographic vasospasm.
This study aims to identify potential epigenetic biomarkers for aSAH susceptibility and DIND risk, which could improve early diagnosis and risk stratification in affected patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* subarachnoid hemorrhage in computed tomography (CT) scan
* ruptured aneurysm identified with angio-CT or digital subtraction angiography (DSA)
* aneurysm successfully embolized or clipped
* obtained informed consent
* Hunt-Hess grade ≤ 3 by day 14 (initial higher grade was allowed providing that patient improved to grade 3 or higher by day 14)
Exclusion Criteria:
* \< 18 years old
* unable to sign informed consent
* diagnosis of idiopathic perimesencephalic subarachnoid hemorrhage
* aneurysm identified more than 14 days after the ictus
* more than 14 days at the Intensive Care Unit
* remaining in Hunt Hess grade 5 or World Federation of Neurological Surgeons (WFNS) grade 5 from admission up to post-bleeding day 14
Primary outcome measure(s)
DNA methylation changes associated with aneurysmal subarachnoid hemorrhage and delayed ischemic neurologic deficit — Within four days following the enrollment (as blood samples will be collected within days 1-4 post-hemorrhage). Methylation profiling and CpG analysis the entire batch will be conducted within one year following enrollment of the last participant Identification of differentially methylated CpG sites in peripheral blood DNA of patients with aneurysmal subarachnoid hemorrhage compared to healthy controls and to assess whether DNA methylation changes are associated with delayed ischemic neurologic deficit.
The metrics and direction of DNA methylation changes will be reported as Δβ values
Trial sites (1)
Facility
City
Region
Status
Pomeranian Medical University Hospital No. 1
Szczecin
West Pomeranian Voivodeship
More Pomeranian Medical University Szczecin trials in Poland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.